Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching between originator and biosimilar adalimumab or etanercept in children with juvenile idiopathic arthritis in remission
2021-004031-86Phase 4Active
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Sep 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of adalimumab and etanercept in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Primary endpoint: Clinical remission. Started Sep 2021; status: active.
02
Drugs
adalimumabetanercept
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2021-004031-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004031-86.